{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:07:10Z","timestamp":1785517630606,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40266-026-01319-4","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:34:29Z","timestamp":1784111669000},"page":"721-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Age on Bleeding, Stroke, and Mortality in Edoxaban-Treated Patients with Atrial Fibrillation: Results from the ETAF-TR Registry"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7841-0227","authenticated-orcid":false,"given":"O\u011fuzhan","family":"\u00c7elik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6384-6455","authenticated-orcid":false,"given":"Ozcan","family":"Basaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-2236","authenticated-orcid":false,"given":"Turhan","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-4603","authenticated-orcid":false,"given":"Selim","family":"Kul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6348-6616","authenticated-orcid":false,"given":"Ugur Onsel","family":"Turk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"17","key":"1319_CR1","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1161\/CIRCULATIONAHA.117.028981","volume":"136","author":"C Magnussen","year":"2017","unstructured":"Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation. 2017;136(17):1588\u201397. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028981.","journal-title":"Circulation"},{"issue":"9","key":"1319_CR2","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1161\/STROKEAHA.114.006070","volume":"45","author":"L Friberg","year":"2014","unstructured":"Friberg L, Rosenqvist M, Lindgren A, Ter\u00e9nt A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke. 2014;45(9):2599\u2013605. https:\/\/doi.org\/10.1161\/STROKEAHA.114.006070.","journal-title":"Stroke"},{"issue":"11","key":"1319_CR3","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1161\/STROKEAHA.113.002329","volume":"44","author":"S Bj\u00f6rck","year":"2013","unstructured":"Bj\u00f6rck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.113.002329.","journal-title":"Stroke"},{"issue":"1","key":"1319_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000548492","volume":"72","author":"J Wolfes","year":"2026","unstructured":"Wolfes J, Colla CA, Frommeyer G, Ellermann C, Eckardt L. AF-CARE in the elderly: implications of the 2024 ESC guideline on the management of atrial fibrillation in older patients. Gerontology. 2026;72(1):54\u201362. https:\/\/doi.org\/10.1159\/000548492.","journal-title":"Gerontology"},{"issue":"5","key":"1319_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"key":"1319_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fmed.2019.00175","volume":"6","author":"Z Zathar","year":"2019","unstructured":"Zathar Z, Karunatilleke A, Fawzy AM, Lip GYH. Atrial fibrillation in older people: concepts and controversies. Front Med (Lausanne). 2019;6:175. https:\/\/doi.org\/10.3389\/fmed.2019.00175.","journal-title":"Front Med (Lausanne)."},{"issue":"6","key":"1319_CR7","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s12325-021-01769-9","volume":"38","author":"G Botto","year":"2021","unstructured":"Botto G, Ameri P, Cappellari M, et al. Unmet clinical needs in elderly patients receiving direct oral anticoagulants for stroke prevention in non-valvular atrial fibrillation. Adv Ther. 2021;38(6):2891\u2013907. https:\/\/doi.org\/10.1007\/s12325-021-01769-9.","journal-title":"Adv Ther"},{"issue":"7","key":"1319_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1105594","volume":"367","author":"JB Olesen","year":"2012","unstructured":"Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1105594.","journal-title":"N Engl J Med"},{"issue":"7","key":"1319_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14072328","volume":"14","author":"I Parrini","year":"2025","unstructured":"Parrini I, Luc\u00e0 F, Rao CM, et al. Management of atrial fibrillation in elderly patients: a whole new ballgame? J Clin Med. 2025;14(7):2328. https:\/\/doi.org\/10.3390\/jcm14072328.","journal-title":"J Clin Med"},{"issue":"22","key":"1319_CR10","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"issue":"1","key":"1319_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-019-1144-x","volume":"19","author":"R De Caterina","year":"2019","unstructured":"De Caterina R, Kelly P, Monteiro P, et al. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovasc Disord. 2019;19(1):165. https:\/\/doi.org\/10.1186\/s12872-019-1144-x.","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"1319_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5543\/tkda.2022.21065","volume":"50","author":"U \u00d6nselT\u00fcrk","year":"2022","unstructured":"\u00d6nselT\u00fcrk U, Alio\u011flu E, Mavio\u011flu Z, Diker E, \u00d6zpelit E, De Caterina R. Evaluation of treatment safety in patients with atrial fibrillation on edoxaban therapy in real-life in Turkey study: design and rationale. Turk Kardiyol Dern Ars. 2022;50(2):117\u201323. https:\/\/doi.org\/10.5543\/tkda.2022.21065.","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"2","key":"1319_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.5543\/tkda.2025.82703","volume":"54","author":"U\u00d6 T\u00fcrk","year":"2026","unstructured":"T\u00fcrk U\u00d6, Kocaba\u015f U, Arslan U, et al. Baseline clinical characteristics of patients from the evaluation of treatment safety in patients with atrial fibrillation on edoxaban therapy in real-life in T\u00fcrkiye (ETAF-TR) study. Turk Kardiyol Dern Ars. 2026;54(2):121\u20139. https:\/\/doi.org\/10.5543\/tkda.2025.82703.","journal-title":"Turk Kardiyol Dern Ars"},{"issue":"7","key":"1319_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/europace\/eut395","volume":"16","author":"GJ Wynn","year":"2014","unstructured":"Wynn GJ, Todd DM, Webber M, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014;16(7):965\u201372. https:\/\/doi.org\/10.1093\/europace\/eut395.","journal-title":"Europace"},{"issue":"36","key":"1319_CR15","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"issue":"5","key":"1319_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15051955","volume":"15","author":"AM L\u00f3pez-Pena","year":"2026","unstructured":"L\u00f3pez-Pena AM, Elices-Teja J, Dur\u00e1n-Bob\u00edn O, et al. Age-related differences in the clinical profile and management of atrial fibrillation: results from the multicentre REGUEIFA registry. J Clin Med. 2026;15(5):1955. https:\/\/doi.org\/10.3390\/jcm15051955.","journal-title":"J Clin Med"},{"issue":"5","key":"1319_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003432","volume":"5","author":"ET Kato","year":"2016","unstructured":"Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5(5):e003432. https:\/\/doi.org\/10.1161\/JAHA.116.003432.","journal-title":"J Am Heart Assoc"},{"key":"1319_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fmed.2020.00107","volume":"7","author":"K Deng","year":"2020","unstructured":"Deng K, Cheng J, Rao S, Xu H, Li L, Gao Y. Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis. Front Med (Lausanne). 2020;7:107. https:\/\/doi.org\/10.3389\/fmed.2020.00107.","journal-title":"Front Med (Lausanne)."},{"key":"1319_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-025-01272-8","author":"T Galvain","year":"2026","unstructured":"Galvain T, Hill R, Donegan S, Wilkinson R, Lip GYH, Czanner G. Efficacy and safety of DOACs in patients with atrial fibrillation and history of falls or risk of falls: the Liverpool AF-Falls project. A systematic review and Bayesian network meta-analysis. Drugs Aging. 2026. https:\/\/doi.org\/10.1007\/s40266-025-01272-8.","journal-title":"Drugs Aging"},{"issue":"4","key":"1319_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70011","volume":"55","author":"B Kefale","year":"2025","unstructured":"Kefale B, Peterson GM, Mirkazemi C, et al. Does hospitalisation improve oral anticoagulant optimisation in patients with atrial fibrillation? Eur J Clin Investig. 2025;55(4):e70011. https:\/\/doi.org\/10.1111\/eci.70011.","journal-title":"Eur J Clin Investig"},{"issue":"4","key":"1319_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/PTS.0000000000000924","volume":"18","author":"WM Bezabhe","year":"2022","unstructured":"Bezabhe WM, Bereznicki LR, Radford J, Wimmer BC, Salahudeen MS, Peterson GM. Eight-year trends in direct-acting oral anticoagulant dosing, based on age and kidney function, in patients with atrial fibrillation. J Patient Saf. 2022;18(4):337\u201341. https:\/\/doi.org\/10.1097\/PTS.0000000000000924.","journal-title":"J Patient Saf"},{"issue":"3","key":"1319_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/clc.70091","volume":"48","author":"R De Caterina","year":"2025","unstructured":"De Caterina R, Unverdorben M, Chen C, et al. Two-year follow-up of patients with atrial fibrillation receiving edoxaban in routine clinical practice: results from the global ETNA-AF program. Clin Cardiol. 2025;48(3):e70091. https:\/\/doi.org\/10.1002\/clc.70091.","journal-title":"Clin Cardiol"},{"issue":"9","key":"1319_CR23","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamacardio.2024.1793","volume":"9","author":"A Zimerman","year":"2024","unstructured":"Zimerman A, Braunwald E, Steffel J, et al. Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol. 2024;9(9):817\u201325. https:\/\/doi.org\/10.1001\/jamacardio.2024.1793.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"1319_CR24","doi-asserted-by":"publisher","first-page":"e2228500","DOI":"10.1001\/jamanetworkopen.2022.28500","volume":"5","author":"S Akashi","year":"2022","unstructured":"Akashi S, Oguri M, Ikeno E, et al. Outcomes and safety of very-low-dose edoxaban in frail patients with atrial fibrillation in the ELDERCARE-AF randomized clinical trial. JAMA Netw Open. 2022;5(8):e2228500. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.28500.","journal-title":"JAMA Netw Open"},{"key":"1319_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131618","volume":"398","author":"R Cemin","year":"2024","unstructured":"Cemin R, Cappato R. Lessons derived from post authorisation safety studies (ETNA-AF and XANTUS) on once daily direct oral anticoagulants for atrial fibrillation. Int J Cardiol. 2024;398:131618. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131618.","journal-title":"Int J Cardiol"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01319-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01319-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01319-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:26:46Z","timestamp":1785515206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01319-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1319"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01319-4","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ETAF-TR study was funded by Daiichi Sankyo T\u00fcrkiye. No author received personal fees, honoraria, or other direct compensation from Daiichi Sankyo in relation to this manuscript. On behalf of the ETAF-TR Investigators, Associate Professor Oguzhan Celik declares that no other conflicts of interest relevant to the contents of this manuscript exist.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: UOT; data curation: OC and TT; formal analysis: SK and OB; investigation: OB and OC; methodology: OC and UOT; project administration: OB and OC; writing\u2014original draft: OC, OB, and UOT; and writing\u2014review and editing: all authors.","order":2,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ETAF-TR study protocol was approved by the local ethics committee (513-SBKAEK, 2020\/04-01) and the Turkish Medicines and Medical Devices Agency (TITCK) in March 2020.","order":4,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants included in the study.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have approved the final version of the manuscript for publication.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}